Advances in the Treatment of HIV: Focus on Newer Strategies
In this presentation, Dr. Andrew Zolopa, Professor Emeritus of Medicine at Stanford School of Medicine, discusses the history of antiretroviral therapy (ART) in HIV-infected patients. He highlights some of the potential long-term risks of ART regimens in this patient population. Dr. Zolopa describes the recent advances in the treatment of HIV-infected patients, such as two-drug regimens which have been included in clinical guidelines, and long-acting injectable drugs that are being evaluated in clinical trials.
In the second part of his presentation, Dr. Zolopa examines the different strategies and challenges of treating viral suppressed HIV-infected patients versus treatment-naïve patients.
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Stanford University School of Medicine
Nothing to disclose.
Professor Emeritus Stanford University School of Medicine
- Retroviridae Infections
- Infectious Disease Medicine
- Long Term Adverse Effects
- Drug-Related Side Effects and Adverse Reactions
- Viral Load
- Sexually Transmitted Diseases, Viral
- Anti-Retroviral Agents
- HIV Protease Inhibitors
- HIV Long-Term Survivors
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- HIV Infections